Cardiac Biomarker Change at 1 Year After Tafamidis Treatment and Clinical Outcomes in Patients With Transthyretin Amyloid Cardiomyopathy
2024; Wiley; Volume: 13; Issue: 10 Linguagem: Inglês
10.1161/jaha.124.034518
ISSN2047-9980
AutoresNaoto Kuyama, Seiji Takashio, Tetsuya Oguni, Masahiro Yamamoto, Kyoko Hirakawa, Masanobu Ishii, Shinsuke Hanatani, Seitaro Oda, Yasushi Matsuzawa, Hiroki Usuku, Eiichiro Yamamoto, Toshinori Hirai, Mitsuharu Ueda, Kenichi Tsujita,
Tópico(s)Neuroendocrine Tumor Research Advances
ResumoAlthough tafamidis treatment improves prognosis in patients with wild-type transthyretin amyloid cardiomyopathy, an optimal surrogate marker monitoring its therapeutic effect remains unclear. This study investigated the association between changes in cardiac biomarkers, high-sensitivity cardiac troponin T (hs-cTnT) and B-type natriuretic peptide (BNP) during the first year after tafamidis treatment and clinical outcomes.
Referência(s)